Emcure Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.38%

Emcure Pharmaceuticals Ltd (EMCURE) has an Asset Resilience Ratio of 1.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Emcure Pharmaceuticals Ltd (EMCURE) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs1.29 Billion

≈ $13.98 Million USD Cash + Short-term Investments

Total Assets

Rs93.93 Billion

≈ $1.02 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2025)

This chart shows how Emcure Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Emcure Pharmaceuticals Ltd.

Liquid Assets Composition Over Time

This chart breaks down Emcure Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Emcure Pharmaceuticals Ltd (EMCURE) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs1.29 Billion	1.38%
Total Liquid Assets	Rs1.29 Billion	1.38%

Asset Resilience Insights

Limited Liquidity: Emcure Pharmaceuticals Ltd maintains only 1.38% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Emcure Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Emcure Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	5.50%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Natco Pharma Limited NSE:NATCOPHARM	Drug Manufacturers - Specialty & Generic	63.89%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%

Annual Asset Resilience Ratio for Emcure Pharmaceuticals Ltd (2022–2025)

The table below shows the annual Asset Resilience Ratio data for Emcure Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	0.92%	Rs760.43 Million ≈ $8.22 Million	Rs82.33 Billion ≈ $890.34 Million	-2.78pp
2024-03-31	3.70%	Rs2.89 Billion ≈ $31.28 Million	Rs78.06 Billion ≈ $844.21 Million	+0.64pp
2023-03-31	3.06%	Rs2.04 Billion ≈ $22.11 Million	Rs66.73 Billion ≈ $721.61 Million	+0.66pp
2022-03-31	2.40%	Rs1.46 Billion ≈ $15.74 Million	Rs60.63 Billion ≈ $655.74 Million	--

pp = percentage points

About Emcure Pharmaceuticals Ltd

NSE:EMCURE India Drug Manufacturers - Specialty & Generic

Market Cap

$4.00 Billion

Rs370.10 Billion INR

Market Cap Rank

#4114 Global

#181 in India

Share Price

Rs1952.10

Change (1 day)

-1.49%

52-Week Range

Rs1271.80 - Rs2009.60

All Time High

Rs2009.60